- Centers & Specialties
- Clinical Interests
- Lung cancer
- Targeted therapies for the treatment of lung cancer
- Medical Education
- MD, PhD, Albert Einstein College of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
Stand Up to Cancer (SU2C) and the American Cancer Society (ACS) announced the formation of a new Dream Team to tackle the problem of lung cancer during the annual meeting of the American Association of Cancer Research (AACR) held April 20 in Philadelphia.
Jeffrey A. Engelman, MD, PhD, associate professor of medicine at Harvard Medical School and director of thoracic oncology at Massachusetts General Hospital Cancer Center, will be leader of a $20 million Dream Team to attack the number one cancer killer in America, lung cancer.
A new screening platform using cells grown directly from tumor biopsy samples may lead to truly individualized treatment strategies that would get around the problem of treatment resistance, which limits the effectiveness of current targeted therapy drugs.
The Henri and Belinda Termeer Center for Targeted Therapies in the MGH Cancer Center has three new endowed leadership positions.
A new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
Combination therapy may benefit patients with specific genetic subtype of non-small cell lung cancer
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth.
55 Fruit Street
Boston MA, 02114-2696